Lipid peroxidation and Copper-Zinc Superoxide Dismutase activity in patients treated with fluoxetine during the first episode of depression;Peroksydacja lipidów i aktywność cynkowo-miedziowej dysmutazy ponadtlenkowej u osób leczonych fluoksetyna̧ z powodu pierwszego epizodu depresji

Psychiatria Polska

Volumn 41, Issue 5, 2007, Pages 615-624

  Gałecki, Piotr ^a   Kȩdziora, Józef ^b   Florkowski, Antoni ^a   Gałecka, Elzbieta ^b  

^a Klinika Psychiatrii Doros ych UM W Odzi   (Poland)

^b Katedra I Zak ad Chemii I Biochemii Klinicznej UM W Odzi   (Poland)

Author keywords

Depression; Fluoxetine; Human; Lipid peroxidation; Superoxide dismutase

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; CASE CONTROL STUDY; DEPRESSION; DRUG EFFECT; ENZYMOLOGY; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; METABOLISM; PILOT STUDY; THROMBOCYTE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD PLATELETS; CASE-CONTROL STUDIES; DEPRESSION; FEMALE; FLUOXETINE; HUMANS; LIPID PEROXIDATION; MALE; PILOT PROJECTS; SUPEROXIDE DISMUTASE; TREATMENT OUTCOME;

EID: 43749101521     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Pużyński S. Depressive disorders in general medical practice, particularly in basic health care. Psychiatr Pol. 2000; 34 (1): 47-58.
2. Jacobs BL, Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol. Psychiatry 2000; 5 (3): 262-269.
3. McEwen BS, Magarinos AM. Stress and hippocampal plasticity: implications for the pathophysiology of affective disorders. Hum. Psychopharmacol. 2001; 16: 7-19.
4. Dranovsky A, Hen R. Hippocampal neurogenesis: regulation by stress and antidepressants. Biol. Psychiatry 2006; 59 (12): 1136-1143.
5. Reines A, Cereseto M, Ferrero A, Bonavita C, Wikinski S. Neuronal cytoskeletal alterations in an experimental model of depression. Neurosc. 2004; 129 (3): 529-538.
6. Conrad CD, LeDoux JE, Magarinos AM, McEwen BS. Repeated restraint stress facilitates fear conditioning independently of causing hippocampal CA3 dendritic atrophy. Behav. Neurosc. 1999; 113 (5): 902-913.
7. Magarinos AM, Deslandes A, McEwen BS. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur. J. Pharmacol. 1999; 371 (2-3): 113-122.
8. Newton SS, Duman RS. Regulation of neurogenesis and angiogenesis in depression. Curr. Neurovasc. Res. 2004; 1 (3): 261-267.
9. Arantes-Goncalves F, Coelho R. Depression and treatment. Apoptosis, neuroplasticity and antidepressants. Acta Med. Port. 2006; 19 (1): 9-20.
10. D'Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disord. 2002; 4 (3): 183-194.
11. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int. Clin. Psychopharmacol. 2004; 19 (2): 89-95.
12. Pae CU, Yoon SJ, Patkar A, Kim JJ, Jun TY, Lee C, Paik IH. Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism and mood disorders: a preliminary study. Progr. Neuropsychopharmacol. Biol. Psychiatry 2006; 30 (7): 1326-1329.
13. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 1992; 59: 1609-1623.
14. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: A comparison of the Cu,ZnSOD (sod1), Mn-SOD (sod2), and EC-SOD (sod3) gene structures, evolution, and expression. Free Radic. Biol. Med. 2002; 33: 337-349.
15. Chan SH, Wu KL, Wang LL, Chan JY. Nitric oxide- and superoxide-dependent mitochondrial signaling in endotoxin-induced apoptosis in the rostral ventrolateral medulla of rats. Free Radic. Biol. Med. 2005; 39 (5): 603-618.
16. Fujimura M, Tominaga T, Chan PH. Neuroprotective effect of an antioxidant in ischemic brain injury: involvement of neuronal apoptosis. Neurocrit. Care 2005; 2 (1): 59-66.
17. Kamsler A, Segal M. Hydrogen peroxide modulation of synaptic plasticity. J. Neurosc. 2003; 23 (1): 269-276.
18. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry 1999; 4 (4): 317-327.
19. Sapolsky RM. Glucocorticoids, hippocampal damage and the glutamatergic synapse. Progr. Brain Res. 1990; 86: 13-23.
20. Czlonkowska AI, Zienowicz M, Bidzinski A, Maciejak P, Lehner M, Taracha E, Wislowska A, Plaznik A. The role of neurosteroids in the anxiolytic, antidepressive and anticonvulsive effects of selective serotonin reuptake inhibitors. Med. Sc. Monit. 2003; 9 (11): 270-275.
21. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR. Cytokines and serotonin transporter in patients with major depression. Progr. Neuropsychopharmacol. Biol. Psychiatry 2006; 30 (5): 899-905.
22. Kolla N, Wei Z, Richardson JS, Li XM. Amitriptyline and fluoxetine protect PC12 cells from cell death induced by hydrogen peroxide. J. Psychiatry Neurosc. 2005; 30 (3): 196-201.
23. Li BS, Ji HA, Liu GQ. Doxepin protects cultured neurons against oxidative stress - induced injury. Acta Pharmacol. Sin. 2004; 25: 297-300.
24. Barradas MA, Mikhailidis DP. The use of platelets as models for neurons: possible applications to the investigation of eating disorders. Biomed. Pharmacother. 1993; 47: 11-18.
25. Dreux C, Launay JM. Blood platelets: neuronal model in psychiatric disorders. Enceph. 1985; 11: 57-64.
26. Malmgren R, Hasselmark L. The platelet and the neuron: two cells in focus in migraine. Cephal. 1988; 8: 7-24.
27. Plein H, Berk M. The platelet as a peripheral marker in psychiatric illness. Hum. Psychopharmacol. 2001; 16: 229-236.
28. Klasyfikacja zaburzeń psychicznych i zaburzeń zachowania w ICD-10. Opisy kliniczne i wskazówki diagnostyczne. Kraków- Warszawa: Uniwersyteckie Wydawnictwo Medyczne "Vesalius"; 1997.
29. Bech P. i in. Scale for the assessment of diagnosis and severity of mental disorders. Acta Psychiatr. Scand. 1993, 87 (supl.): 372.
30. Hamilton M. Developmant of a rating scale for primary depressive illness. Brit. J. Social. Clin. Psychol. 1967; 6: 278-296.
31. Shafer AB. Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. J. Clin. Psychol. 2006; 62 (1): 123-146.
32. Misra HP, Fridovich I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem. 1972; 247: 3170-3175.
33. Placer Z, Cushman L, Johnson B. Estimation of product of lipid peroxidation malondialdehyde in biochemical systems. Anal. Bioch. 1966; 16: 359-364.
34. Maier CM, Chan PH. Role of superoxide dismutases in oxidative damage and neurodegenerative disorders. Neuroscien. 2002; 8 (4): 323-334.
35. Kamsler A, Segal M. Paradoxical actions of hydrogen peroxide on long-term potentiation in transgenic superoxide dismutase-1 mice. J. Neurosc. 2003; 23 (32): 10359-10367.
36. Schmuck G, Rohrdanz E, Tran-Thi QH, Kahl R, Schluter G. Oxidative stress in rat cortical neurons and astrocytes induced by paraquat in vitro. Neurotox Res. 2002; 4 (1): 1-13.
37. Zaheer A, Yang B, Cao X, Lim R. Decreased copper-zinc superoxide dismutase activity and increased resistance to oxidative stress in glia maturation factor-null astrocytes. Neurochem Res. 2004; 29 (8): 1473-1480.
38. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid paroxidation and peroxidative tissue injury. Free Radic. Biol Med. 1990; 9: 515-540.
39. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res. Rev. 2005; 4 (2): 141-194.
40. Tichomirowa MA, Keck ME, Schneider HJ, Paez-Pereda M, Renner U, Holsboer F, Stalla GK. Endocrine disturbances in depression. J. Endocrinol. Invest. 2005; 28 (1): 89-99.
41. Sahin E, Gumuslu S. Alterations in brain antioxidant status, protein oxidation and lipid peroxidation in response to different stress models. Behav. Brain Res. 2004; 155 (2): 241-248.
42. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 2003; 8 (6): 365-370.
43. Kim HJ, Choi JS, Lee YM, Shim EY, Hong SH, Kim MJ, Min DS, Rhie DJ, Kim MS, Jo YH, Hahn SJ, Yoon SH. Fluoxetine inhibits ATP-induced [Ca(2+)](i) increase in PC12 cells by inhibiting both extracellular Ca(2+) influx and Ca(2+) release from intracellular stores. Neuropharmacol. 2005; 49 (2): 265-274.
44. Traboulsie A, Chemin J, Kupfer E, Nargeot J, Lory P. T-type calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine. Mol. Pharmacol. 2006; 69 (6): 1963-1968.